Design, Synthesis, and Biological Evaluation of Novel Quinazoline Derivatives as Anti-inflammatory Agents against Lipopolysaccharide-induced Acute Lung Injury in Rats
inhibition against lipopolysaccharide‐induced TNF‐α and IL‐6 release. Then, the preliminary structure–activityrelationship and quantitative structure–activityrelationship analyses were conducted. To further determine the effects of quinazolines on acutelunginjury treatment, lipopolysaccharide‐induced acutelunginjury model was employed. Male Sprague Dawley rats were pretreated with 6m or 6q before instillation
A class of compounds identified as N-(1-methyl-1H-indol-5-yl)-(2,3 or 4-pyridyl)ureas, derivatives thereof, methods for their preparation, pharmaceutical compositions containing same and their 5-HT receptor antagonist activity are believed to be of potential use in the treatment of a variety of CNS disorders are described herein.
A novel series of 3-alkyl-substituted 7-phenyl-3H-pyrrolo[3,2-jlquinolin-9-ones (7-PPyQs) was synthesized with the aim to optimize the cytotoxic activity of recently identified PPyQs, promising inhibitors of tubulin polymerization. All compounds inhibited the growth of 11 human tumor cell lines at submicromolar concentrations as well as two human resistant cancer sublines, A549-T12 and A549-T24. FACS analysis indicated that all compounds caused significant arrest of the A549 cell cycle in G(2)/M phase at 0.1 and 1 mu M and a good correlation between the cytotoxicity IC50 and their ability to block the cell cycle was observed.
Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors